Literature DB >> 15292530

Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions.

L C Rall1, R Roubenoff.   

Abstract

We have previously identified the phrase 'rheumatoid cachexia' to describe the loss of body cell mass (BCM) that may occur among patients with rheumatoid arthritis (RA). Specifically, rheumatoid cachexia is characterized by altered energy and protein metabolism (reduced total energy expenditure, increased resting energy expenditure and increased whole-body protein catabolism) and increased inflammatory cytokine production (interleukin-1beta and tumour necrosis factor-alpha). Patients with rheumatoid cachexia consistently have a diet that appears adequate in protein and calories (based on US Dietary Reference Intakes), but with reduced physical activity. These phenomena are similar to some of the metabolic abnormalities that occur with normal ageing, but the aetiology appears to be different in RA. This review will focus on describing the metabolic abnormalities observed in rheumatoid cachexia, identifying potential mechanisms for loss of BCM and discussing strategies for intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292530     DOI: 10.1093/rheumatology/keh321

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  72 in total

1.  Body composition abnormalities in long-term survivors of pediatric hematopoietic stem cell transplantation.

Authors:  Sogol Mostoufi-Moab; Jill P Ginsberg; Nancy Bunin; Babette S Zemel; Justine Shults; Meena Thayu; Mary B Leonard
Journal:  J Pediatr       Date:  2011-08-11       Impact factor: 4.406

2.  Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis.

Authors:  Rachel A Brown; Domenico Spina; Sayqa Butt; Gregory D Summers
Journal:  Clin Rheumatol       Date:  2011-10-19       Impact factor: 2.980

3.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

4.  Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis.

Authors:  M Otero; R Lago; R Gomez; F Lago; C Dieguez; J J Gómez-Reino; O Gualillo
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

5.  TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study.

Authors:  Éric Toussirot; Laurent Mourot; Barbara Dehecq; Daniel Wendling; Émilie Grandclément; Gilles Dumoulin
Journal:  Eur J Nutr       Date:  2013-10-31       Impact factor: 5.614

Review 6.  Growth abnormalities in children and adolescents with juvenile idiopathic arthritis.

Authors:  Susanne Bechtold; Dominique Simon
Journal:  Rheumatol Int       Date:  2014-04-24       Impact factor: 2.631

7.  Granulocyte chemotaxis and disease expression are differentially regulated by GRK subtype in an acute inflammatory arthritis model (K/BxN).

Authors:  Teresa K Tarrant; Rishi R Rampersad; Denise Esserman; Lisa R Rothlein; Peng Liu; Richard T Premont; Robert J Lefkowitz; David M Lee; Dhavalkumar D Patel
Journal:  Clin Immunol       Date:  2008-07-26       Impact factor: 3.969

8.  Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Karen M J Douglas; Helen R Griffiths; George D Kitas
Journal:  Arthritis Res Ther       Date:  2008-12-17       Impact factor: 5.156

9.  Locomotion and muscle mass measures in a murine model of collagen-induced arthritis.

Authors:  Anita Hartog; Judith Hulsman; Johan Garssen
Journal:  BMC Musculoskelet Disord       Date:  2009-06-03       Impact factor: 2.362

10.  Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study.

Authors:  Tracey E Toms; Vasileios F Panoulas; Holly John; Karen M J Douglas; George D Kitas
Journal:  Arthritis Res Ther       Date:  2009-07-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.